Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Complera Launch Imminent Following FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.

You may also be interested in...



Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making

Amgen moves into the chimeric antigen receptor T-cell space in cancer under a complex partnership with Kite Pharma. Gilead, Isis and Janssen agree to multiple deals during and after the holiday season, while scuttled deals return assets or rights to Vanda, AMAG and OncoGenex.

Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo

Just weeks after the apparently successful launch of its HIV “quad pill,” Gilead already is talking up a new compound with potential as part of an HIV combination therapy. And in HCV, the company is preparing a new study without partner Bristol-Myers Squibb.

Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera

Company is pursuing priority review, eyes FDA approval in mid-2012. If Quad is cleared, newly approved Complera will take back seat.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072629

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel